Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow in Infectious Diseases, Medicine, Duke University 2007 - 2009
  • Chief Medical Resident - VAMC, Medicine, Duke University 2006 - 2007
  • Medical Resident, Medicine, Duke University 2002 - 2005
  • M.D., Johns Hopkins University 2002
• 

  Duke Appointment History

  • Associate Professor of Medicine, Medicine, Infectious Diseases, Medicine 2015 - 2017
  • Assistant Professor of Medicine, Medicine, Infectious Diseases, Medicine 2009 - 2015
  • Medical Instructor in the Department of Medicine, Medicine, General Internal Medicine, Medicine 2005 - 2007
• Recognition
• 

  In the News

  • JUN 19, 2015

    Duke Human Vaccine Team Awarded $5 million To Study Fungal Fever
• Research
• 

  Selected Grants

  • mHealth Peer Support to Reduce Rates of STIs in Black MSM PrEP Users awarded by National Institutes of Health 2018 - 2023
  • A Clinic-Based Behavioral Intervention to Reduce Cardiovascular Disease Risk in Persons Living with HIV awarded by National Institutes of Health 2018 - 2022
  • Duke Resident Physician-Scientist Program- NIAID awarded by National Institutes of Health 2018 - 2022
  • Identification of Novel Bioactive Lipid Metabolites for Predicting Liver-related Outcomes in Persons Co-Infected with HIV and HCV awarded by National Institutes of Health 2017 - 2022
  • Duke Training Grant in Digestive Diseases and Nutrition awarded by National Institutes of Health 1988 - 2021
  • VTEU: Task Area D: Research Laboratory Analysis Protocol #14-0053 awarded by National Institutes of Health 2015 - 2021
  • Interdisciplinary Research Training Program in AIDS awarded by National Institutes of Health 2010 - 2020
  • First-in-human (FIH) Safety and Dose Ranging Study of TT-034 in Patients with Chronic Hepatitis C (CHC) Infection awarded by Tacere Therapeutics 2014 - 2020
  • M16-135 awarded by AbbVie Inc. 2017 - 2019
  • VTEU: Task Area C: Protocol Implementation - Option 2 Protocol #14-0053 awarded by National Institutes of Health 2015 - 2019
  • Molecular Mycology and Pathogenesis Training Program awarded by National Institutes of Health 2002 - 2019
  • HCV/HIV Co-infection Registry awarded by Gilead Sciences, Inc. 2015 - 2019
  • RCT of an Integrated Treatment of Persons with Co-Occurring HCV and Alcohol Abuse awarded by National Institutes of Health 2013 - 2019
  • Randomized Trial to Prevent Vascular Events in HIV- REPRIEVE (A5332) awarded by Massachusetts General Hospital 2015 - 2019
  • B2801001 Follow Up Study awarded by Tacere Therapeutics 2014 - 2019
  • ACTG, Aids Clinical Trials Group Hepatitis TSG Vice-Chair awarded by Brigham and Women's Hospital 2015 - 2018
  • Systems Biology Approaches for Predicting Cardiometabolic Risk in Persons Living with HIV awarded by National Institutes of Health 2015 - 2018
  • GS-US-366-1992 awarded by Gilead Sciences, Inc. 2016 - 2018
  • ACTG A5327 Protocol Chair Support (PCS) awarded by Brigham and Women's Hospital 2015 - 2017
  • VTEU: Base -Task Area A: Project Logistics and Site Activation Protocol #14-0053 awarded by National Institutes of Health 2015 - 2017
  • Gilead - GS-US-342-1202 awarded by Gilead Sciences, Inc. 2015 - 2017
  • Gilead GS-342-1553 awarded by Gilead Sciences, Inc. 2014 - 2017
  • GS_US_342-1140 awarded by Gilead Sciences, Inc. 2014 - 2017
  • VTEU: Option 1-Task Area B: Protocol Development Protocol #14-0053 awarded by National Institutes of Health 2015 - 2016
  • The Pharmacokinetics of Extended Duration High-dose Cefixime Co-administered with Azithromycin for the Decreased Susceptibility of Neisseria gonorrhoeae: A Phase I Pilot Study awarded by National Institutes of Health 2015 - 2016
  • GS-US-337-0115 awarded by Gilead Sciences, Inc. 2014 - 2016
  • ACTG, Aids Clinical Trials Group awarded by Brigham and Women's Hospital 2015
  • Moving Towards More Individualized Therapies in HIV/HCV Co-infected Patients awarded by National Institutes of Health 2011 - 2015
  • Collaboration between Duke University and the NIAID awarded by National Institutes of Health 2010 - 2012
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • AASLD-IDSA HCV Guidance Panel, . "Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America 67, no. 10 (October 2018): 1477-1492.  Full Text
    • Proeschold-Bell, RJ, Evon, DM, Makarushka, C, Wong, JB, Datta, SK, Yao, J, Patkar, AA, Mannelli, P, Hodge, T, Naggie, S, Wilder, JM, Fried, MW, Niedzwiecki, D, and Muir, AJ. "The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial." Contemporary Clinical Trials 72 (September 2018): 73-85.  Full Text
    • MacBrayne, CE, Marks, KM, Fierer, DS, Naggie, S, Chung, RT, Hughes, MD, Kim, AY, Peters, MG, Brainard, DM, Seifert, SM, Castillo-Mancilla, JR, Bushman, LR, Anderson, PL, and Kiser, JJ. "Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate." The Journal of Antimicrobial Chemotherapy 73, no. 8 (August 2018): 2112-2119.  Full Text
    • Okeke, NL, Alenezi, F, Bloomfield, GS, Dunning, A, Clement, ME, Shah, SH, Naggie, S, and Velazquez, EJ. "Determinants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort." Journal of Cardiac Failure 24, no. 8 (August 2018): 496-503.  Full Text
    • Naggie, S, Clement, M, Lusk, S, Osinusi, A, Himmel, T, Lucas, JE, Thompson, WJ, Dubois, L, Moseley, MA, Clark, PJ, Kottilil, S, and Patel, K. "Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations." Proteomics. Clinical Applications (July 30, 2018): e1800006-null.  Full Text
    • Naggie, S, Swiderska-Syn, M, Choi, S, Lusk, S, Lan, A, Ferrari, G, Syn, W-K, Guy, CD, and Diehl, AM. "Markers of Tissue Repair and Cellular Aging Are Increased in the Liver Tissue of Patients With HIV Infection Regardless of Presence of HCV Coinfection." Open Forum Infectious Diseases 5, no. 7 (July 2018): ofy138-null.  Full Text
    • Clement, ME, Collins, LF, Wilder, JM, Mugavero, M, Barker, T, and Naggie, S. "Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure." Infectious Disease Clinics of North America 32, no. 2 (June 2018): 407-423. (Review)  Full Text
    • Carlton-Smith, C, Holmes, JA, Naggie, S, Lidofsky, A, Lauer, GM, Kim, AY, Chung, RT, and of the ACTG A5327 study group, . "IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR." Journal of Viral Hepatitis 25, no. 5 (May 2018): 465-472.  Full Text
    • Kleinstein, SE, Shea, PR, Stamm, LM, Sulkowski, M, Goldstein, DB, and Naggie, S. "Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America (March 7, 2018).  Full Text
    • Okeke, NL, Craig, DM, Muehlbauer, MJ, Ilkayeva, O, Clement, ME, Naggie, S, and Shah, SH. "Metabolites predict cardiovascular disease events in persons living with HIV: a pilot case–control study." Metabolomics 14, no. 3 (March 2018).  Full Text
    • Clement, ME, Lin, L, Navar, AM, Okeke, NL, Naggie, S, and Douglas, PS. "Lower likelihood of cardiac procedures after acute coronary syndrome in patients with human immunodeficiency virus/acquired immunodeficiency syndrome." Medicine 97, no. 6 (February 2018): e9849-null.  Full Text
    • Collins, LF, Chan, A, Zheng, J, Chow, S-C, Wilder, JM, Muir, AJ, and Naggie, S. "Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection." Open forum infectious diseases 5, no. 1 (January 2018): ofx264-.  Full Text  Open Access Copy
    • Morgan, JR, Kim, AY, Naggie, S, and Linas, BP. "The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets." Open forum infectious diseases 5, no. 1 (January 2018): ofx267-.  Full Text
    • Lok, AS, Chung, RT, Vargas, HE, Kim, AY, Naggie, S, and Powderly, WG. "Benefits of direct-acting antivirals for Hepatitis C." Annals of Internal Medicine 167, no. 11 (December 5, 2017): 812-813.  Full Text
    • Lok, AS, Chung, RT, Vargas, HE, Kim, AY, Naggie, S, and Powderly, WG. "Benefits of Direct-Acting Antivirals for Hepatitis C." Annals of Internal Medicine 167, no. 11 (December 2017): 812-813.  Full Text
    • Zuckerman, A, Chastain, CA, and Naggie, S. "Retreatment Options Following HCV Direct Acting Antiviral Failure." Current treatment options in infectious diseases 9, no. 4 (December 2017): 389-402.  Full Text
    • Babich, T, Zusman, O, Elbaz, M, Ben-Zvi, H, Paul, M, Leibovici, L, and Avni, T. "Empirical Antibiotic Treatment Does Not Improve Outcomes in Catheter-Associated Urinary Tract Infection: Prospective Cohort Study." Clinical Infectious Diseases 65, no. 11 (November 13, 2017): 1799-1805.  Full Text
    • Powderly, WG, Naggie, S, Kim, AY, Vargas, HE, Chung, RT, and Lok, AS. "IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America 65, no. 11 (November 2017): 1773-1775.  Full Text
    • Lok, AS, Chung, RT, Vargas, HE, Kim, AY, Naggie, S, and Powderly, WG. "Comments on cochrane review on direct-acting antivirals for hepatitis C." Hepatology (Baltimore, Md.) 66, no. 4 (October 2017): 1016-1019.  Full Text
    • Wyles, D, Bräu, N, Kottilil, S, Daar, ES, Ruane, P, Workowski, K, Luetkemeyer, A, Adeyemi, O, Kim, AY, Doehle, B, Huang, KC, Mogalian, E, Osinusi, A, McNally, J, Brainard, DM, McHutchison, JG, Naggie, S, Sulkowski, M, and ASTRAL-5 Investigators, . "Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America 65, no. 1 (July 2017): 6-12.  Full Text
    • Burton, MJ, and Naggie, S. "Real-World Effectiveness of DAA Therapies in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection: 996 Veterans Can't Be Wrong." Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 64, no. 12 (June 2017): 1721-1723.  Full Text
    • Naggie, S, Marks, KM, Hughes, M, Fierer, DS, Macbrayne, C, Kim, A, Hollabaugh, K, Roa, J, Symonds, B, Brainard, DM, McHutchison, JG, Peters, MG, Kiser, JJ, Chung, R, and Team, ACTGAS. "Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C." CLINICAL INFECTIOUS DISEASES 64, no. 8 (April 15, 2017): 1035-1042.  Full Text  Link to Item
    • Chan, A, Patel, K, and Naggie, S. "Genotype 3 Infection: The Last Stand of Hepatitis C Virus." Drugs 77, no. 2 (February 2017): 131-144. (Review)  Full Text
    • Ho, SB, Monto, A, Peyton, A, Kaplan, DE, Byrne, S, Moon, S, Copans, A, Rossaro, L, Roy, A, Le, H, Dvory-Sobol, H, Zhu, Y, Brainard, DM, Guyer, W, Shaikh, O, Fuchs, M, Morgan, TR, and VALOR study team, . "Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities." Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association 15, no. 2 (February 2017): 282-288.  Full Text
    • Naggie, S. "Hepatitis C Virus, Inflammation, and Cellular Aging: Turning Back Time." Topics in Antiviral Medicine 25, no. 1 (February 2017): 3-6. (Review)
    • Alam, I, Brown, K, Donovan, C, Forlenza, J, Lauwers, K, Mah'moud, MA, Manch, R, Mohanty, SR, Prabhakar, A, Reindollar, R, DeMasi, R, Slim, J, Tandon, N, Villadiego, S, and Naggie, S. "Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study." Open Forum Infectious Diseases 4, no. 1 (January 2017): ofw258-null.  Full Text
    • Naggie, S, Holland, DP, Sulkowski, MS, and Thomas, DL. "Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 64, no. 1 (January 2017): 92-99. (Review)  Full Text
    • Naggie, S, and Muir, AJ. "Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs." Annual Review of Medicine 68 (January 2017): 345-358. (Review)  Full Text
    • Younossi, ZM, Stepanova, M, Sulkowski, M, Naggie, S, Henry, L, and Hunt, S. "Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus." JOURNAL OF VIRAL HEPATITIS 23, no. 11 (November 2016): 857-865.  Full Text  Link to Item
    • Katrak, S, Park, LP, Woods, C, Muir, A, Hicks, C, and Naggie, S. "Patterns of Healthcare Utilization Among Veterans Infected With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) and Coinfected With HIV/HCV: Unique Burdens of Disease." Open forum infectious diseases 3, no. 3 (September 2016): ofw173-.  Full Text
    • Wong, TC, Lan, A, Kiser, JJ, Anderson, PL, Patel, K, Tillman, H, and Naggie, S. "Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression." Hepatology (Baltimore, Md.) 64, no. 3 (September 2016): 999-1000. (Letter)  Full Text
    • Clement, ME, Park, LP, Navar, AM, Okeke, NL, Pencina, MJ, Douglas, PS, and Naggie, S. "Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study." Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 63, no. 3 (August 2016): 407-413.  Full Text
    • Cooper, C, Naggie, S, Saag, M, Yang, JC, Stamm, LM, Dvory-Sobol, H, Han, L, Pang, PS, McHutchison, JG, Dieterich, D, and Sulkowski, M. "Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America 63, no. 4 (August 2016): 528-531.  Full Text
    • Bhagani, S, Cooper, C, Naggie, S, Saag, M, Yang, J, Stamm, L, Natha, M, Dvory-Sobol, H, McHutchinson, J, Jackson, A, Dieterich, D, and Sulkowski, M. "Retreatment of patients co-infected with HCV and HIV-1 who failed 12 weeks of ledipasvir/sofosbuvir." HIV MEDICINE 17 (April 2016): 38-38.  Link to Item
    • Suhy, D, Patel, K, Kilfoil, G, Wyles, DL, Naggie, S, Lawitz, E, Bradley, S, and Lindell, P. "Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi) delivered as a single administration for the treatment of subjects with chronic hepatitis C virus (HCV)." HEPATOLOGY 62, no. 6 (December 2015): 1386A-1386A.  Link to Item
    • Muir, AJ, and Naggie, S. "Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?." Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association 13, no. 12 (November 2015): 2166-2172. (Review)  Full Text
    • AASLD/IDSA HCV Guidance Panel, . "Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus." Hepatology (Baltimore, Md.) 62, no. 3 (September 2015): 932-954. (Review)  Full Text
    • Rockstroh, J, Cooper, C, Naggie, S, Saag, M, Yang, J, Stamm, L, Pang, P, McHutchison, J, Dieterich, D, and Sulkowski, M. "A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection: the Phase 3 ION-4 study." JOURNAL OF VIRAL HEPATITIS 22 (September 2015): 24-24.  Link to Item
    • Naggie, S, Cooper, C, Saag, M, Workowski, K, Ruane, P, Towner, WJ, Marks, K, Luetkemeyer, A, Baden, RP, Sax, PE, Gane, E, Santana-Bagur, J, Stamm, LM, Yang, JC, German, P, Dvory-Sobol, H, Ni, L, Pang, PS, McHutchison, JG, Stedman, CAM, Morales-Ramirez, JO, Braeu, N, Jayaweera, D, Colson, AE, Tebas, P, Wong, DK, Dieterich, D, Sulkowski, M, and Investigators, I. "Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1." NEW ENGLAND JOURNAL OF MEDICINE 373, no. 8 (August 20, 2015): 705-713.  Full Text  Link to Item
    • Naggie, S, Cooper, C, Saag, M, Workowski, K, Ruane, P, Towner, WJ, Marks, K, Luetkemeyer, A, Baden, RP, Sax, PE, Gane, E, Santana-Bagur, J, Stamm, LM, Yang, JC, German, P, Dvory-Sobol, H, Ni, L, Pang, PS, McHutchison, JG, Stedman, CAM, Morales-Ramirez, JO, Bräu, N, Jayaweera, D, Colson, AE, Tebas, P, Wong, DK, Dieterich, D, Sulkowski, M, and ION-4 Investigators, . "Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1." The New England Journal of Medicine 373, no. 8 (August 2015): 705-713.  Full Text
    • Younossi, ZM, Stepanova, M, Sulkowski, M, Naggie, S, Puoti, M, Orkin, C, and Hunt, SL. "Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes." The Journal of Infectious Diseases 212, no. 3 (August 2015): 367-377.  Full Text
    • Naggie, S, Cooper, C, Saag, M, Yang, JC, Stamm, LM, Pang, PS, McHutchison, JG, Dieterich, D, and Sulkowski, MS. "Ledipasvir/sofosbuvir for 12 weeks in patients co-infected with HCV and HIV-1." JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 18 (July 2015).  Full Text  Link to Item
    • Horner, SM, and Naggie, S. "Successes and Challenges on the Road to Cure Hepatitis C." Plos Pathogens 11, no. 6 (June 18, 2015): e1004854-null. (Review)  Full Text  Open Access Copy
    • Matthews, GV, Neuhaus, J, Bhagani, S, Mehta, SH, Vlahakis, E, Doroana, M, Naggie, S, Arenas-Pinto, A, Peters, L, Rockstroh, JK, and International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group, . "Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial." Hiv Medicine 16 Suppl 1 (April 2015): 129-136.  Full Text
    • Naggie, S, Patel, K, Yang, L-Y, Chow, S-C, Johnson, V, Guyton, JR, Muir, AJ, Sulkowski, M, and Hicks, C. "Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected Individuals." Open forum infectious diseases 2, no. 2 (April 2015): ofv066-.  Full Text
    • Meissner, EG, Lee, Y-J, Osinusi, A, Sims, Z, Qin, J, Sturdevant, D, McHutchison, J, Subramanian, M, Sampson, M, Naggie, S, Patel, K, Remaley, AT, Masur, H, and Kottilil, S. "Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients." Hepatology (Baltimore, Md.) 61, no. 3 (March 2015): 790-801.  Full Text
    • Naggie, S, and Kim, AY. "PHOTON-2: hope for patients with HIV and HCV co-infection?." Lancet (London, England) 385, no. 9973 (March 2015): 1052-1054.  Full Text
    • "PHOTON-2: Hope for patients with HIV and HCV co-infection?." The Lancet 385, no. 9973 (January 1, 2015): 1052-1054.  Full Text
    • Norton, B, and Naggie, S. "The clinical management of HCV in the HIV-infected patient." Antiviral therapy 20, no. 5 (January 2015): 457-467. (Review)  Full Text
    • Sulkowski, MS, Naggie, S, Lalezari, J, Fessel, WJ, Mounzer, K, Shuhart, M, Luetkemeyer, AF, Asmuth, D, Gaggar, A, Ni, L, Svarovskaia, E, Brainard, DM, Symonds, WT, Subramanian, GM, McHutchison, JG, Rodriguez-Torres, M, Dieterich, D, and PHOTON-1 Investigators, . "Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection." Jama 312, no. 4 (July 2014): 353-361.  Full Text
    • Molina, JM, Naggie, S, Sulkowski, M, Lalezari, J, Mchutchison, J, Dieterich, D, and Rodriguez-Torres, M. "[In Process Citation]." Medecine et maladies infectieuses 44, no. 6 Suppl (June 2014): 1-2.  Full Text
    • Norton, BL, Voils, CI, Timberlake, SH, Hecker, EJ, Goswami, ND, Huffman, KM, Landgraf, A, Naggie, S, and Stout, JE. "Community-based HCV screening: Knowledge and attitudes in a high risk urban population." Bmc Infectious Diseases 14, no. 1 (March 10, 2014).  Full Text
    • Norton, BL, Voils, CI, Timberlake, SH, Hecker, EJ, Goswami, ND, Huffman, KM, Landgraf, A, Naggie, S, and Stout, JE. "Community-based HCV screening: knowledge and attitudes in a high risk urban population." BMC infectious diseases 14 (February 10, 2014): 74-.  Full Text  Open Access Copy
    • Goswami, ND, Tsalik, EL, Naggie, S, Miller, WC, Horton, JR, Pfeiffer, CD, and Hicks, CB. "A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: the relationship between industry sponsorship and randomized study design." Trials 15 (January 22, 2014): 31-.  Full Text
    • Bruno, TO, Hicks, CB, Naggie, S, Wohl, DA, Albrecht, H, Thielman, NM, Rabin, DU, Layton, S, Subramaniam, C, Grichnik, KP, Shlien, A, and Weyer, D. "VISION: a regional performance improvement initiative for HIV health care providers." The Journal of continuing education in the health professions 34, no. 3 (January 2014): 171-178.  Full Text
    • Chastain, CA, and Naggie, S. "Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014." Curr HIV/AIDS Rep 10, no. 4 (December 2013): 408-419. (Review)  Full Text  Link to Item
    • Chastain, CA, and Naggie, S. "Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014." Current HIV/AIDS Reports 10, no. 4 (December 1, 2013): 408-419.  Full Text
    • Osinusi, A, and Naggie, S. "Boceprevir for HCV in patients with HIV: where next?." The Lancet. Infectious Diseases 13, no. 7 (July 2013): 563-564.  Full Text
    • Osinusi, A, and Naggie, S. "Boceprevir for HCV in patients with HIV: Where next?." The Lancet Infectious Diseases 13, no. 7 (2013): 563-564.  Full Text
    • Naggie, S. "Management of hepatitis C virus infection: the basics." Topics in Antiviral Medicine 20, no. 5 (December 2012): 154-161. (Review)
    • Osinusi, A, Chary, A, Winters, MA, Naggie, S, Masur, H, Polis, MA, Kottilil, S, and Holodniy, M. "IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin." J Med Virol 84, no. 10 (October 2012): 1522-1527.  Full Text  Link to Item
    • Clark, PJ, Thompson, AJ, Zhu, Q, Vock, DM, Zhu, M, Patel, K, Harrison, SA, Naggie, S, Ge, D, Tillmann, HL, Urban, TJ, Shianna, K, Fellay, J, Goodman, Z, Noviello, S, Pedicone, LD, Afdhal, N, Sulkowski, M, Albrecht, JK, Goldstein, DB, McHutchison, JG, and Muir, AJ. "Erratum to: The Association of Genetic Variants with Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C Infection." Digestive Diseases and Sciences 57, no. 9 (September 2012): 2479-2479.  Full Text
    • Norton, BL, Park, L, McGrath, LJ, Proeschold Bell, RJ, Muir, AJ, and Naggie, S. "Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection." Aids Patient Care and Stds 26, no. 9 (September 2012): 541-545.  Full Text
    • Clark, PJ, Thompson, AJ, Zhu, Q, Vock, DM, Zhu, M, Patel, K, Harrison, SA, Naggie, S, Ge, D, Tillmann, HL, Urban, TJ, Shianna, K, Fellay, J, Goodman, Z, Noviello, S, Pedicone, LD, Afdhal, N, Sulkowski, M, Albrecht, JK, Goldstein, DB, McHutchison, JG, and Muir, AJ. "The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection." Dig Dis Sci 57, no. 8 (August 2012): 2213-2221.  Full Text  Link to Item
    • Naggie, S, Osinusi, A, Katsounas, A, Lempicki, R, Herrmann, E, Thompson, AJ, Clark, PJ, Patel, K, Muir, AJ, McHutchison, JG, Schlaak, JF, Trippler, M, Shivakumar, B, Masur, H, Polis, MA, and Kottilil, S. "Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response." Hepatology (Baltimore, Md.) 56, no. 2 (August 2012): 444-454.  Full Text
    • Osinusi, A, Naggie, S, Poonia, S, Trippler, M, Hu, Z, Funk, E, Schlaak, J, Fishbein, D, Masur, H, Polis, M, and Kottilil, S. "ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV." Journal of Medical Virology 84, no. 7 (July 2012): 1106-1114.  Full Text
    • Clark, PJ, Thompson, AJ, Zhu, M, Vock, DM, Zhu, Q, Ge, D, Patel, K, Harrison, SA, Urban, TJ, Naggie, S, Fellay, J, Tillmann, HL, Shianna, K, Noviello, S, Pedicone, LD, Esteban, R, Kwo, P, Sulkowski, MS, Afdhal, N, Albrecht, JK, Goldstein, DB, McHutchison, JG, Muir, AJ, and IDEAL investigators, . "Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response." J Viral Hepat 19, no. 5 (May 2012): 332-340.  Full Text  Link to Item
    • Naggie, S, and Sulkowski, MS. "Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals." Gastroenterology 142, no. 6 (May 2012): 1324-1334.e3. (Review)  Full Text
    • Rallón, NI, Soriano, V, Naggie, S, Restrepo, C, McHutchison, J, Vispo, E, and Benito, JM. "Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV." J Antimicrob Chemother 67, no. 5 (May 2012): 1246-1249.  Full Text  Link to Item
    • Jazwinski, AB, Thompson, AJ, Clark, PJ, Naggie, S, Tillmann, HL, and Patel, K. "Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis." J Viral Hepat 19, no. 4 (April 2012): 278-282.  Full Text  Link to Item
    • Proeschold-Bell, RJ, Patkar, AA, Naggie, S, Coward, L, Mannelli, P, Yao, J, Bixby, P, and Muir, AJ. "An integrated alcohol abuse and medical treatment model for patients with hepatitis C." Digestive Diseases and Sciences 57, no. 4 (April 2012): 1083-1091.  Full Text  Open Access Copy
    • Naggie, S, Rallon, NI, Benito, JM, Morello, J, Rodriguez-Novoa, S, Clark, PJ, Thompson, AJ, Shianna, KV, Vispo, E, McHutchison, JG, Goldstein, DB, and Soriano, V. "Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes." The Journal of Infectious Diseases 205, no. 3 (February 2012): 376-383.  Full Text
    • Thompson, AJ, Clark, PJ, Singh, A, Ge, D, Fellay, J, Zhu, M, Zhu, Q, Urban, TJ, Patel, K, Tillmann, HL, Naggie, S, Afdhal, NH, Jacobson, IM, Esteban, R, Poordad, F, Lawitz, EJ, McCone, J, Shiffman, ML, Galler, GW, King, JW, Kwo, PY, Shianna, KV, Noviello, S, Pedicone, LD, Brass, CA, Albrecht, JK, Sulkowski, MS, Goldstein, DB, McHutchison, JG, and Muir, AJ. "Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients." Journal of Hepatology 56, no. 2 (February 2012): 313-319.  Full Text
    • "The role of IL28B genotype testing in the era of direct acting antiviral agents." European Gastroenterology and Hepatology Review 8, no. 1 (January 1, 2012): 33-39.
    • Goswami, ND, Hecker, EJ, Vickery, C, Ahearn, MA, Cox, GM, Holland, DP, Naggie, S, Piedrahita, C, Mosher, A, Torres, Y, Norton, BL, Suchindran, S, Park, PH, Turner, D, and Stout, JE. "Geographic information system-based screening for TB, HIV, and syphilis (GIS-THIS): a cross-sectional study." PLoS One 7, no. 10 (2012): e46029-.  Full Text  Open Access Copy  Link to Item
    • Osinusi, A, and Naggie, S. "The Role of IL28B Genotype Testing in the Era of Direct Acting Antiviral Agents." European gastroenterology & hepatology review 1, no. 2 (January 2012): 33-39.
    • Goswami, ND, Hecker, E, Holland, DP, Naggie, S, Cox, GM, Mosher, A, Turner, D, Torres, Y, Vickery, C, Ahearn, MA, Blain, MLM, Rasmussen, P, and Stout, JE. "Feasibility and willingness-to-pay for integrated community-based tuberculosis testing. (Published online)" BMC Infect Dis 11 (November 2, 2011): 305-.  Full Text  Open Access Copy  Link to Item
    • Sidique, N, Kohli, A, Shivakumar, B, Migueles, S, Subramanian, GM, Naggie, S, Polis, MA, Masur, H, and Kottilil, S. "HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients." Journal of Acquired Immune Deficiency Syndromes (1999) 58, no. 2 (October 2011): e38-e40. (Letter)  Full Text
    • Barreiro, P, Pineda, JA, Rallón, N, Naggie, S, Martín-Carbonero, L, Neukam, K, Rivero, A, Benito, JM, Caruz, A, Vispo, E, Camacho, A, Medrano, J, McHutchison, J, and Soriano, V. "Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy." The Journal of Infectious Diseases 203, no. 11 (June 2011): 1629-1636.  Full Text
    • Jazwinski, A, Naggie, S, and Perfect, J. "Immune reconstitution syndrome in a patient with disseminated histoplasmosis and steroid taper: maintaining the perfect balance." Mycoses 54, no. 3 (May 2011): 270-272. (Letter)  Full Text  Link to Item
    • Rallón, NI, Soriano, V, Naggie, S, Restrepo, C, Goldstein, D, Vispo, E, McHutchison, J, and Benito, JM. "IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin." Aids (London, England) 25, no. 8 (May 2011): 1025-1033.  Full Text
    • Naggie, SN. "Investigational Agents for Chronic Viral Infections: HIV and HCV." JOURNAL OF NEUROIMMUNE PHARMACOLOGY 6 (April 2011): S18-S18.  Link to Item
    • Naggie, S, Miller, BA, Zuzak, KB, Pence, BW, Mayo, AJ, Nicholson, BP, Kutty, PK, McDonald, LC, and Woods, CW. "A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors." Am J Med 124, no. 3 (March 2011): 276.e1-276.e7.  Full Text  Link to Item
    • Thompson, AJ, Santoro, R, Piazzolla, V, Clark, PJ, Naggie, S, Tillmann, HL, Patel, K, Muir, AJ, Shianna, KV, Mottola, L, Petruzzellis, D, Romano, M, Sogari, F, Facciorusso, D, Goldstein, DB, McHutchison, JG, and Mangia, A. "Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR." Hepatology (Baltimore, Md.) 53, no. 2 (February 2011): 389-395.  Full Text
    • Rallon, NI, Restrepo, C, Naggie, S, Lopez, M, Del Romero, J, Goldstein, D, McHutchison, J, Soriano, V, and Benito, JM. "Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline." AIDS 25, no. 2 (January 14, 2011): 269-271.  Full Text  Link to Item
    • Rallón, NI, Soriano, V, Naggie, S, Restrepo, C, Goldstein, D, Vispo, E, McHutchison, J, and Benito, JM. "IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin." AIDS 25, no. 8 (2011): 1025-1033.  Full Text
    • Thompson, AJ, Muir, AJ, Sulkowski, MS, Patel, K, Tillmann, HL, Clark, PJ, Naggie, S, Fellay, J, Ge, D, McCarthy, JJ, Goldstein, DB, and McHutchison, JG. "Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype." Hepatology (Baltimore, Md.) 52, no. 6 (December 2010): 2243-2244. (Letter)  Full Text
    • Thompson, AJ, Santoro, R, Piazzolla, V, Clark, PJ, Naggie, S, Tillmann, HL, Patel, K, Muir, AJ, Shianna, KV, Mottola, L, Petruzzellis, D, Romano, M, Sogari, F, Facciorusso, D, Goldstein, DB, McHutchison, JG, and Mangia, A. "Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR." Hepatology (November 12, 2010).  Full Text  Link to Item
    • Medrano, J, Neukam, K, Rallón, N, Rivero, A, Resino, S, Naggie, S, Caruz, A, Calvino, A, Macías, J, Benito, JM, Sánchez-Piedra, C, Vispo, E, Barreiro, P, McHutchison, J, Pineda, JA, and Soriano, V. "Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America 51, no. 10 (November 2010): 1209-1216.  Full Text
    • Naggie, S, Patel, K, and McHutchison, J. "Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors." The Journal of Antimicrobial Chemotherapy 65, no. 10 (October 2010): 2063-2069. (Review)  Full Text
    • Thompson, AJ, Fellay, J, Patel, K, Tillmann, HL, Naggie, S, Ge, D, Urban, TJ, Shianna, KV, Muir, AJ, Fried, MW, Afdhal, NH, Goldstein, DB, and McHutchison, JG. "Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction." Gastroenterology 139, no. 4 (October 2010): 1181-1189.  Full Text
    • Person, AK, Goswami, ND, Bissette, DJ, Turner, DS, Baker, AV, Gadkowski, LB, Naggie, S, Erlandson, K, Chen, L, Lalani, T, Cox, GM, and Stout, JE. "Pairing QuantiFERON gold in-tube with opt-out HIV testing in a tuberculosis contact investigation in the Southeastern United States." Aids Patient Care and Stds 24, no. 9 (September 2010): 539-543.  Full Text  Open Access Copy
    • Naggie, S, Frederick, J, Pien, BC, Miller, BA, Provenzale, DT, Goldberg, KC, and Woods, CW. "Community-associated Clostridium difficile infection: experience of a veteran affairs medical center in southeastern USA." Infection 38, no. 4 (August 2010): 297-300.  Full Text  Link to Item
    • Naggie, S, and Hicks, C. "Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options." J Antimicrob Chemother 65, no. 6 (June 2010): 1094-1099. (Review)  Full Text  Link to Item
    • Rallón, NI, Naggie, S, Benito, JM, Medrano, J, Restrepo, C, Goldstein, D, Shianna, KV, Vispo, E, Thompson, A, McHutchison, J, and Soriano, V. "Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients." Aids (London, England) 24, no. 8 (May 2010): F23-F29.  Full Text
    • Kutty, PK, Woods, CW, Sena, AC, Benoit, SR, Naggie, S, Frederick, J, Evans, S, Engel, J, and McDonald, LC. "Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA." Emerg Infect Dis 16, no. 2 (February 2010): 197-204.  Full Text  Open Access Copy  Link to Item
    • Naggie, S, Hseih, T, Reckleff, J, Castellano, J, and Hicks, CB. "Treatment and CD4+ T cell count recovery among antiretroviral therapy-naive patients with HIV/AIDS." Clin Infect Dis 49, no. 10 (November 15, 2009): 1619-1620. (Letter)  Full Text  Link to Item
    • Naggie, S, and Perfect, JR. "Molds: hyalohyphomycosis, phaeohyphomycosis, and zygomycosis." Clin Chest Med 30, no. 2 (June 2009): 337-viii. (Review)  Full Text  Link to Item
    • Kutty, PK, Benoit, SR, Woods, CW, Sena, AC, Naggie, S, Frederick, J, Engemann, J, Evans, S, Pien, BC, Banerjee, SN, Engel, J, and McDonald, LC. "Assessment of Clostridium difficile-associated disease surveillance definitions, North Carolina, 2005." Infection Control and Hospital Epidemiology 29, no. 3 (March 2008): 197-202.  Full Text
    • Morpeth, SC, Crump, JA, Shao, HJ, Ramadhani, HO, Kisenge, PR, Moylan, CA, Naggie, S, Caram, LB, Landman, KZ, Sam, NE, Itemba, DK, Shao, JF, Bartlett, JA, and Thielman, NM. "Predicting CD4 lymphocyte count <200 cells/mm(3) in an HIV type 1-infected African population." Aids Research and Human Retroviruses 23, no. 10 (October 2007): 1230-1236.  Full Text
    • Pham, MQ, Naggie, S, Wier, M, Cha, HJ, and Bentley, WE. "Human interleukin-2 production in insect (Trichoplusia ni) larvae: effects and partial control of proteolysis." Biotechnol Bioeng 62, no. 2 (January 20, 1999): 175-182.  Link to Item
    • Naggie, S, and Bentley, WE. "Appearance of protease activities coincides with p10 and polyhedrin-driven protein production in the baculovirus expression system: effects on yield." Biotechnol Prog 14, no. 2 (March 1998): 227-232.  Full Text  Link to Item
    • NAGGIE, S. "Appearance of protease activities coincides with p10 and polyhedrin-driven protein production in the baculovirus expression system : effects on yield." Biotechnol. Prog. 14 (1998): 227-232.  Full Text
    • Naggie, S, Hu, YC, Pulliam-Holoman, TR, and Bentley, WE. "Substrate (gelatin) gel electrophoretic method for analysis of protease activity in insect (Sf-9) cells." Biotechnology Techniques 11, no. 5 (January 1, 1997): 297-300.  Full Text

  • Conference Papers

    • Naggie, S, Fierer, DS, Hughes, M, Kim, AY, Luetkemeyer, A, Vu, V, Roa, J, Brainard, DM, McHutchison, JG, Peters, MG, Kiser, JJ, Marks, KM, and Chung, RT. "100% SVR with 8 weeks of ledipasvir/sofosbuvir in HIV-infected Men with Acute HCV Infection: Results from the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals)." October 2017.  Link to Item
    • Naggie, S, Marks, KM, Hughes, M, Fierer, DS, Macbrayne, C, Kim, A, Hollabaugh, K, Roa, J, Symonds, B, Brainard, DM, McHutchison, JG, Peters, MG, Kiser, JJ, Chung, R, and AIDS Clinical Trials Group (ACTG) A5327 Study Team, . "Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C." April 2017.  Full Text
    • Younossi, ZM, Stepanova, M, Sulkowski, M, Naggie, S, Henry, L, and Hunt, S. "Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus." November 2016.  Full Text
    • Asselah, T, Shiha, G, Feld, JJ, Abergel, A, Kohli, A, Kottilil, S, Ruane, PJ, Naggie, S, Letterio, C, Hahambis, TA, Llewellyn, J, Natha, M, Kersey, K, McNally, J, Brainard, DM, and Esmat, GE. "Integrated Analysis of SOF plus RBV, LDV/SOF or SOF/VEL for the Treatment of Genotype 4 Chronic HCV Infection." October 2016.  Link to Item
    • Chan, AW, Bryan, WE, Hashem, MA, Townsend, ML, Wang, LA, Choi, SS, and Naggie, S. "Hepatitis C (HCV) Virologic Outcomes in Veterans taking Ledipasvir/Sofosbuvir with Concomitant Acid Suppressing Medication." October 2016.  Link to Item
    • Fuchs, M, Morgan, TR, Charafeddine, M, Brau, N, Schmidt, WN, Kozal, M, Naggie, S, Cheung, R, Pilot-Matias, T, Yu, Y, Richards, K, Mullally, V, Cohen, DE, Monto, A, and Toro, DH. "An Open-Label, Multicenter Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in US Veterans with Genotype 1 Chronic Hepatitis C Infection: Efficacy and Safety Results of TOPAZ-VA." October 2016.  Link to Item
    • Naggie, S, Rosenthal, E, Kattakuzhy, S, McGinnis, J, Naik, S, Natha, M, Llewellyn, J, Haubrich, R, Osinusi, AO, Stamm, LM, Cooper, C, Dieterich, DT, and Sulkowski, MS. "Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) in Patients Coinfected With HCV and HIV-1: A Comparative Analysis of Clinical Trials with Four Real World Cohorts." October 2016.  Link to Item
    • Sulkowski, MS, Cooper, C, Molina, J-M, Naggie, S, Huang, KC, Osinusi, AO, Stamm, LM, Massetto, B, McNally, J, Brainard, DM, McHutchison, JG, Wyles, DL, Rockstroh, JK, and Dieterich, DT. "High Rates of Medical and Psychiatric Comorbidities in HIV/HCV Coinfected Patients Treated With Sofosbuvir-Containing Regimens in Registrational Clinical Trials." October 2016.  Link to Item
    • Wyles, D, Brau, N, Naggie, S, Sulkowski, M, Agarwal, K, Patel, K, Afdhal, N, Liu, L, Ding, X, Huang, K-C, Osinusi, A, McNally, J, Brainard, D, Mertens, M, and McHutchison, J. "SOF/VEL single-tablet regimen in HCV mono-infected and HIV/HCV co-infected patients: comparison of efficacy and safety data from phase 3 clinical trials." October 2016.  Link to Item
    • Braeu, N, Wyles, D, Kottilil, S, Darr, E, Workowski, K, Luetkemeyer, A, Adeyemi, O, Ruane, P, Doehle, B, Huang, KC, Osinusi, A, McNally, J, Natha, M, Guion, M, McLean, T, Brainard, DM, McHutchison, JG, Naggie, S, and Sulkowski, M. "Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase." July 2016.  Link to Item
    • Patel, K, Kilfoil, G, Wyles, DL, Naggie, S, Lawitz, E, Bradley, S, Lindell, P, and Suhy, D. "258. Phase I/IIa Study of TT-034, a DNA-Directed RNA Interference (ddRNAi) Agent Delivered as a Single Administration for the Treatment of Subjects with Chronic Hepatitis C Virus (HCV)." May 2016.  Full Text
    • Alam, I, Brown, K, Donovan, C, Forlenza, J, Lauwers, K, Mah'moud, MA, Manch, RA, Mohanty, SR, Prabhakar, A, Reindollar, R, Sawyerr, G, Slim, J, Tandon, P, Villadiego, S, and Naggie, S. "Su1426 Effectiveness of Simeprevir-Containing Regimens Among Patients With Chronic Hepatitis C Virus in Various US Practice Settings: The SONET Study." April 2016.  Full Text
    • Ruane, PJ, Shiha, G, Abergel, A, Asselah, T, Kohli, A, Kottilil, S, Naggie, S, Doss, W, Esmat, G, Letterio, CM, Hahambis, TA, Natha, M, Kreter, B, Kersey, K, Brainard, D, and Knox, S. "756 Integrated Analysis of Sof+RBV or LDV/Sof for the Treatment of Genotype 4 Chronic HCV Infection." April 2016.  Full Text
    • Alam, I, Brown, K, Donovan, C, Forlenza, J, Lauwers, K, Mah’moud, MA, Manch, R, Mohanty, SR, Prabhakar, A, Reindollar, R, Sawyerr, G, Slim, J, Tandon, N, Villadiego, S, and Naggie, S. "Effectiveness of Simeprevir-Containing Regimens among Patients with Chronic Hepatitis C Virus in Various Us Practice Settings: The Sonet Study." 2016.  Full Text
    • Esmat, GE, Shiha, G, Abergel, A, Asselah, T, Kohli, A, Kottilil, S, Ruane, PJ, Naggie, S, Doss, WH, Hahambis, TA, Letterio, C, Natha, M, Kreter, B, Kersey, K, Brainard, D, and Knox, SJ. "INTEGRATED ANALYSIS OF SOF plus RBV OR LDV/SOF FOR THE TREATMENT OF GENOTYPE 4 CHRONIC HCV INFECTION." 2016.  Link to Item
    • Wyles, D, Brau, N, Kottilil, S, Daar, E, Workowski, K, Luetkemeyer, A, Adeyemi, O, Ruane, P, Doehle, B, Huang, K, Osinusi, A, McNally, J, Brainard, D, McHutchison, J, Naggie, S, and Sulkowski, M. "Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study." 2016.  Full Text
    • Rabatin, A, Hashem, M, Townsend, ML, Bryan, WE, Moylan, CA, Choi, SS, and Naggie, S. "Treatment Outcomes of Veterans with Decompensated Cirrhosis Receiving All Oral Direct Acting Antiviral Hepatitis C Therapy." October 2015.  Link to Item
    • Alam, I, Manch, R, Naggie, S, Reindollar, R, Slim, J, Prabhakar, A, Lauwers, K, Donovan, C, Tandon, N, Forlenza, J, and Brown, K. "P0826 : Effectiveness of simeprevir (SMV)-containing regimens among patients with chronic hepatitis C virus (HCV) in various us practice settings: Interim analysis of the sonet study." April 2015.  Full Text
    • Cooper, C, Naggie, S, Saag, M, Yang, J, Stamm, L, Pang, P, McHutchison, J, Dieterich, D, and Sulkowski, M. "P1353 : A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection : The phase 3 ION-4 study." April 2015.  Full Text
    • Naggie, S, Alam, I, Manch, RA, Reindollar, R, Slim, J, Prabhakar, A, Lauwers, K, Donovan, C, Tandon, N, Forlenza, JB, and Brown, K. "Effectiveness of Simeprevir (SMV) - Containing Regimens Among Patients With Chronic Hepatitis C Virus (HCV) in Various US Practice Settings: Interim Analysis of the Sonet Study." April 2015.  Link to Item
    • Swiderska-Syn, M, Choi, S, Lan, A, Ferrari, G, Diehl, A, and Naggie, S. "P0469 : Markers of tissue repair and cellular aging are increased in liver tissue of patients with dual chronic HIV/HCV infections." April 2015.  Full Text
    • Naggie, S, Sulkowski, M, Gaggar, A, Stamm, L, Ni, L, Brainard, D, Symonds, W, McHutchison, J, Dieterich, D, and Rodriguez-Torres, M. "P1173 THE IMPACT OF HIV CO-INFECTION ON RATES AND SEVERITY OF ANEMIA OCCURRING DURING TREATMENT WITH SOFOSBUVIR-CONTAINING HCV REGIMENS: A POOLED ANALYSIS." April 2014.  Full Text
    • Rockstroh, JK, Puoti, M, Rodriguez-Torres, M, Dieterich, D, Gaggar, A, Ni, L, Massetto, B, Svarovskaia, ES, Brainard, DM, Subramanian, M, McHutchison, JG, Naggie, S, Orkin, C, Molina, J-M, and Sulkowski, MS. "Sofosbuvir and Ribavirin therapy for the Treatment of HIV/HCV coinfected patients with HCV GT1-4 Infection: The PHOTON-1 and-2 Trials." 2014.  Link to Item
    • Younossi, Z, Stepanova, M, Sulkowski, MS, Naggie, S, and Hunt, SL. "Patient-Reported Outcomes (PROs) in HIV-HCV Co-infected Patients Treated with Sofosbuvir (SOF)-containing Regimens." 2014.  Link to Item
    • Sulkowski, MS, Rodriguez-Torres, M, Lalezari, JP, Fessel, WJ, Mounzer, K, Shuhart, MC, Luetkemeyer, A, Asmuth, DM, Gaggar, A, Symonds, WT, McHutchison, JG, Naggie, S, and Dieterich, DT. "All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1)." October 2013.  Link to Item
    • Clark, PJ, Santoro, R, Piazzolla, V, Mottola, L, Bacca, D, Dello Iacono, N, Grimaldi, S, Quarta, A, Urban, TJ, Naggie, S, Patel, K, Thompson, AJ, Muir, AJ, and Mangia, A. "Optimizing ribavirin dose is critical for sustained viral response in patients with thalassemia major treated for chronic hepatitis C." October 2012.  Link to Item
    • Jones, L, Piercy, D, Naggie, S, and Abdelmalek, M. "Drug-Induced Idiopathic Portal Hypertension Mimicking "Cryptogenic" Cirrhosis in a HIV Patient." October 2012.  Link to Item
    • Naggie, S, Osinusi, A, Himmel, T, Lucas, J, Thompson, JW, Dubois, LG, Moseley, MA, Clark, PJ, Kottilil, S, and Patel, K. "Targeted proteomics signature identifies corticosteroid binding globulin peptides as highly predictive of treatment response in IL28B unfavorable genotype patients." October 2012.  Link to Item
    • Clark, PJ, Thompson, AJ, Jazwinski, A, Tillmann, HL, Naggie, S, Muir, AJ, and Patel, K. "Association of Serum Adipocytokines With IL28B and SVR in Chronic Hepatitis C." May 2012.  Link to Item
    • Clark, PJ, Thompson, AJ, Tillmann, HL, Jazwinski, A, Naggie, S, Muir, AJ, and Patel, K. "EXPLORATION OF SERUM ADIPOCYTOKINE ASSOCIATIONS WITH IL28B GENOTYPE IN CHRONIC HEPATITIS C." April 2012.  Full Text  Link to Item
    • Clark, PJ, Thompson, AJ, Urban, TJ, Patel, K, Vock, DM, Zhu, Q, Jazwinski, A, Naggie, S, Tillmann, HL, McKenzie, A, Conjeevaram, HS, Shianna, K, Goldstein, DB, Afdhal, NH, and Muir, AJ. "PNPLA3 GENOTYPE RATHER THAN RACE MAY EXPLAIN THE LOWER PREVALENCE OF HEPATIC STEATOSIS DESPITE WORSE METABOLIC RISK FACTORS IN AFRICAN AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (CHC)." October 2011.  Link to Item
    • Gellad, ZF, Naggie, S, Reed, SD, Clark, PJ, Thompson, AJ, Schulman, KA, and Muir, AJ. "THE COST-EFFECTIVENESS OF A TELAPREVIR-INCLUSIVE REGIMEN AS INITIAL THERAPY FOR GENOTYPE 1 HEPATITIS C INFECTION IN INDIVIDUALS WITH THE CC IL-28B POLYMORPHISM." October 2011.  Link to Item
    • Kohli, A, Naggie, S, Polis, MA, Masur, H, and Kottilil, S. "HIV/HCV-COINFECTED NATURAL VIRAL SUPPRESSORS HAVE BETTER VIROLOGIC RESPONSES TO PEG-IFN AND RIBAVIRIN THAN ARV-TREATED HIV/HCV PATIENTS." October 2011.  Link to Item
    • Osinusi, A, Chary, A, Kottilil, S, Winters, MA, Naggie, S, Masur, H, Polis, MA, and Holodniy, M. "IL28B POLYMORPHISM IS NOT ASSOCIATED WITH HCV PROTEASE DIVERSITY IN HIV/HCV-COINFECTED PATIENTS TREATED WITH AN INTERFERON-BASED REGIMEN." October 2011.  Link to Item
    • Osinusi, A, Naggie, S, Poonia, S, Trippler, M, Hu, Z, Funk, E, Schlaak, JF, Fishbein, D, Masur, H, Polis, MA, and Kottilil, S. "ITPA GENE POLYMORPHISMS SIGNIFICANTLY AFFECT HEMOGLOBIN DECLINE AND TREATMENT OUTCOMES IN HIV/HCV CO-INFECTED PATIENTS." October 2011.  Link to Item
    • Thompson, AJ, Clark, PJ, Tillmann, HL, Patel, K, Naggie, S, Poordad, FF, Lawitz, E, Bacon, BR, Vierling, JM, Noviello, S, Brass, CA, Albrecht, JK, Goldstein, DB, McHutchison, JG, Sulkowski, MS, and Muir, AJ. "IL28B C/C GENOTYPE IS PREDICTIVE OF >= 1 LOG10 IU/ML REDUCTION IN PLASMA HCV RNA AFTER 4 WEEKS OF PEGINTERFERON (PEGIFN) AND RIBAVIRIN (RBV) THERAPY: IMPLICATIONS FOR THE USE OF THE LEAD-IN STRATEGY FOR DIRECT-ACTING ANTIVIRAL-BASED TREATMENT REGIMENS." October 2011.  Link to Item
    • Thompson, AJ, Clark, PJ, Vock, DM, Pfeiffer, R, Tillmann, HL, Patel, K, Naggie, S, Poordad, FF, Nyberg, LM, Noviello, S, Pedicone, L, Brass, CA, Albrecht, JK, Goldstein, DB, McHutchison, JG, O'Brien, TR, Sulkowski, MS, and Muir, AJ. "PREDICTING PEGINTERFERON-alpha AND RIBAVIRIN TREATMENT RESPONSE IN GENOTYPE 1 HCV PATIENTS - SIMPLE NOMOGRAMS TO SUPPORT CLINICIANS." October 2011.  Link to Item
    • Naggie, S, Osinusi, A, Katsounas, A, Lempicki, R, Herrmann, E, Shivakumar, B, Thompson, A, Clark, P, Patel, K, Muir, A, Mchutchison, J, Goldstein, D, Schlaak, J, Masur, H, Polis, M, and Kottilil, S. "DYSREGULATION OF HOST INNATE IMMUNITY IN HCV GENOTYPE 1 INFECTED IL28B CT/TT HAPLOTYPE PATIENTS WITH DEPRESSED VIRAL KINETICS AND THERAPEUTIC RESPONSE." March 2011.  Full Text  Link to Item
    • Rallon, NI, Naggie, S, Restrepo, C, McHutchison, J, Soriano, V, and Benito, JM. "IL28B genotypes strongly influence early viral kinetics in HIV/HCV-coinfected patients treated with peginterferon-alpha/ribavirin - implications using directly acting antivirals." 2011.  Link to Item
    • Clark, PJ, Thompson, AJ, Zhu, M, Zhu, Q, Ge, D, Sulkowski, MS, Tillmann, HL, Patel, K, Naggie, S, Muir, AJ, Afdhal, NH, Jacobson, IM, Esteban, R, Lawitz, E, Poordad, F, Shiffman, ML, Galler, GW, Harrison, S, King, JW, Kwo, PY, Nyberg, LM, McCone, J, Lee, WM, Reindollar, R, Ghalib, RH, Freilich, B, Goodman, Z, Boparai, N, Koury, KJ, Noviello, S, Pedicone, L, Brass, CA, Albrecht, JK, Goldstein, DB, and McHutchison, JG. "IL28B GENETIC POLYMORPHISM HAS GENOME WIDE SIGNIFICANT ASSOCIATIONS WITH SERUM LOW DENSITY LIPOPROTEIN LEVELS AND HEPATIC STEATOSIS IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C (CHC)." October 2010.  Link to Item
    • Naggie, S, Rallon, NI, Benito, JM, Morello, J, Rodriguez-Novoa, S, Clark, PJ, Thompson, AJ, Shianna, K, Vispo, E, McHutchison, JG, Goldstein, DB, and Soriano, V. "VARIANTS IN THE ITPA GENE PROTECT AGAINST EARLY RIBAVIRIN-INDUCED HEMOLYTIC ANEMIA IN HIV/HCV CO-INFECTED PATIENTS." October 2010.  Link to Item
    • Rallon, NI, Naggie, S, Restrepo, C, Goldstein, DB, McHutchison, JG, Soriano, V, and Benito, JM. "THE IL28B CC GENOTYPE STRONGLY PREDICTS EARLY VIRAL KINETICS IN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON-RIBAVIRIN." October 2010.  Link to Item
    • Rollon, NI, Naggie, S, Restrepo, C, Goldstein, DB, McHutchison, JG, Soriano, V, and Benito, JM. "IL28B PLASMA LEVELS IN PATIENTS WITH DISTINCT IL28B SNP POLYMORPHISMS AND ASSOCIATION WITH TREATMENT OUTCOME." October 2010.  Link to Item
    • Thompson, AJ, Clark, PJ, Fellay, J, Muir, AJ, Tillmann, HL, Patel, K, Naggie, S, Afdhal, NH, Jacobson, IM, Esteban, R, Poordad, F, Lawitz, E, McCone, J, Shiffman, ML, Galler, GW, King, JW, Kwo, PY, Nyberg, LM, Goodman, Z, Noviello, S, Boparai, N, Koury, KJ, Pedicone, L, Brass, CA, Albrecht, JK, Goldstein, DB, McHutchison, JG, and Sulkowski, MS. "IL28B GENOTYPE IS NOT ASSOCIATED WITH ADVANCED HEPATIC FIBROSIS IN CHRONIC HEPATITIS C PATIENTS ENROLLED IN THE IDEAL STUDY." October 2010.  Link to Item
    • Thompson, AJ, Clark, PJ, Singh, A, Ge, D, Fellay, J, Sulkowski, MS, Muir, AJ, Tillman, HL, Patel, K, Naggie, S, Shianna, K, Afdhal, NH, Jacobson, IM, Esteban, R, Poordad, F, Lawitz, E, McCone, J, Shiffman, ML, Galler, GW, King, JW, Kwo, PY, Nyberg, L, Noviello, S, Boparai, N, Koury, KJ, Pedicone, L, Brass, CA, Albrecht, JK, Goldstein, DB, and McHutchison, JG. "COMMON GENETIC VARIANTS DO NOT ASSOCIATE WITH IFN-INDUCED NEUTROPENIA IN A GENOME-WIDE ASSOCIATION STUDY OF CHRONIC HEPATITIS C PATIENTS IN THE IDEAL STUDY." October 2010.  Link to Item
    • Thompson, AJ, Clark, PJ, Zhu, M, Zhu, Q, Ge, D, Sulkowski, MS, Muir, AJ, Tillmann, HL, Patel, K, Naggie, S, Afdhal, NH, Jacobsons, IM, Esteban, R, Poordad, F, Lawitz, E, McCone, J, Shiffman, ML, Galler, GW, King, JW, Kwo, PY, Nyberg, LM, Goodman, Z, Noviello, S, Boparai, N, Koury, KJ, Pedicone, L, Brass, C, Albrecht, JK, Goldstein, DB, and McHutchison, JG. "GENOME WIDE-ASSOCIATION STUDY IDENTIFIES IL28B POLYMORPHISM TO BE ASSOCIATED WITH BASELINE ALT AND HEPATIC NECRO-INFLAMMATORY ACTIVITY IN CHRONIC HEPATITIS C PATIENTS ENROLLED IN THE IDEAL STUDY." October 2010.  Link to Item
    • Thompson, AJ, Muir, AJ, Sulkowski, MS, Patel, K, Tillmann, HL, Clark, PJ, Naggie, S, Fellay, J, Ge, D, McCarthy, J, Goldstein, DB, and McHutchison, JG. "HEPATITIS C TRIALS THAT COMBINE INVESTIGATIONAL AGENTS WITH PEGYLATED-INTERFERON-alpha SHOULD BE STRATIFIED BY IL28B GENOTYPE." October 2010.  Link to Item
    • Thompson, AJ, Santoro, R, Piazzolla, V, Tillman, HL, Patel, K, Clark, PJ, Naggie, S, Shianna, K, Mottola, L, Petruzzellis, D, Romano, M, Sogari, F, Facciorusso, D, Goldstein, DB, McHutchison, JG, and Mangia, A. "ITPA GENETIC VARIANTS ARE PROTECTIVE AGAINST ANEMIA DURING ANTIVIRAL THERAPY FOR G2/3 HCV, BUT DO NOT DECREASE THE NEED FOR RBV DOSE REDUCTION OR INCREASE SVR." October 2010.  Link to Item
    • Thompson, AJ, Singh, A, Fellay, J, Ge, D, Sulkowski, MS, Muir, AJ, Tillmann, HL, Patel, K, Naggie, S, Shianna, K, Afdhal, NH, Jacobson, IM, Esteban, R, Poordad, F, Lawitz, E, McCone, J, Shiffman, ML, Galler, GW, King, JW, Kwo, PY, Nyberg, LM, Noviello, S, Boparai, N, Koury, KJ, Pedicone, L, Brass, CA, Albrecht, JK, Goldstein, DB, and McHutchison, JG. "GENOME-WIDE ASSOCIATION STUDY IDENTIFIES AN ASSOCIATION BETWEEN ITPA GENE VARIANTS AND IFN-INDUCED THROMBOCYTOPENIA IN CHRONIC HEPATITIS C PATIENTS FROM THE IDEAL STUDY." October 2010.  Link to Item
    • Naggie, S, Pulliam, TR, and Bentley, WE. "Elicitation of protease activity in insect (Spodoptera frugiperda) cell cultures." March 24, 1996.  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.